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OBJECTIVES The aim of this study was to evaluate myocardial infarction induced by percutaneous
transluminal septal myocardial ablation (PTSMA) in symptomatic patients with hypertrophic
obstructive cardiomyopathy using contrast-enhanced (CE) magnetic resonance imaging
(MRI).
BACKGROUND Contrast-enhanced MRI delineates the extent of myocardial infarction in coronary artery
disease, but its role in ethanol-induced infarction has not been established.
METHODS Cine and CE MRI were performed before and one month after PTSMA in 24 patients. Size
and location of the induced infarction were related to left ventricular (LV) mass reduction,
enzyme release, volume of ethanol administered, LV outflow tract gradient reduction, and
coronary ablation site.
RESULTS One month after PTSMA, regional hyperenhancement was visualized in the basal interven-
tricular septum in all patients. Mean infarction size was 20  9 g, corresponding to 10  5%
and 31  16% of total LV and septal mass, respectively. Total LV mass decreased from
219  64 to 205  64 g (p  0.01), and septal mass from 76  25 to 68  22 g (p  0.01).
Total LV mass reduction exceeded septal mass reduction (p 0.01). Infarction size correlated
with peak creatine phosphokinase-MB ( 0.67, p 0.01), volume of ethanol administered
(  0.47, p  0.02), total LV and septal mass reduction (  0.50, p  0.02;   0.73,
p  0.01), and gradient reduction (  0.63, p  0.01). Seven patients with exclusively
right-sided septal infarction had smaller infarction size and less gradient reduction than
remaining patients with left-sided or transmural infarction (p  0.01). In five of these,
PTSMA was performed distal in the target artery.
CONCLUSIONS Contrast-enhanced MRI allowed detailed evaluation of size and location of septal myocardial
infarction induced by PTSMA. Infarction size correlated well with clinical indexes of infarct
size. (J Am Coll Cardiol 2004;43:27–34) © 2004 by the American College of Cardiology
Foundation
Hypertrophic cardiomyopathy is a heterogeneous disease
characterized by myocardial hypertrophy in the absence of
any other systemic or cardiac disease, with predominant
involvement of the interventricular septum (IVS) (1,2).
Approximately 25% of the patients have a dynamic left
ventricular outflow tract (LVOT) obstruction caused by a
narrowed LVOT and abnormal systolic anterior motion of
the mitral valve.
Treatment strategies in patients with hypertrophic ob-
structive cardiomyopathy (HOCM) who remain symptom-
atic despite optimal medication (beta-adrenergic blocking
agents, verapamil, and disopyramide) include surgical (sep-
tal myotomy-myectomy) and nonsurgical procedures such
as dual-chamber pacing and percutaneous transluminal
septal myocardial ablation (PTSMA) (3–9); PTSMA is a
recently developed procedure, which consists of artificially
inducing a localized myocardial infarct by ethanol infusion
into septal branches of the left anterior descending coronary
artery (7–10). Scarring and thinning of the IVS results in
widening of the LVOT, a decrease of the pressure gradient,
and symptomatic improvement (11–13).
The final outcome after PTSMA is thought to depend on
size and location of the inflicted infarction. Infarcts that are
too small or are located outside the target area may not
achieve the necessary reduction in LVOT gradient. Large
infarcts may cause potentially hazardous conduction abnor-
malities or ventricular arrhythmias. Echocardiography with
intracoronary contrast injection is commonly used during
the procedure to guide the selection of the appropriate
septal branch, but this technique does not allow visualiza-
tion of the infarction site at follow-up. Myocardial perfusion
defects by single-photon emission computed tomographic
myocardial scintigraphy at six weeks after PTSMA corre-
lated with the target area for ablation defined by contrast
echocardiography (14,15). However, the spatial resolution
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of this technique is not sufficient to allow transmural
evaluation.
In patients with ischemic heart disease, contrast-
enhanced (CE) magnetic resonance imaging (MRI) accu-
rately delineates infarcted, irreversibly damaged myocar-
dium, both in the (sub-)acute and in the chronic phases
(16,17). The high spatial resolution of CE MRI would
allow detailed evaluation of the ethanol-induced infarction.
Contrary to contrast echocardiography, CE MRI cannot be
used during the ablation procedure, but it may provide
important feedback by accurately delineating the ultimate
size and location of the infarction. Although CE MRI is
capable of visualizing PTSMA-related infarction, its exact
significance still needs to be established (18).
The purpose of the study was to evaluate myocardial
infarction size and location induced by PTSMA in patients
with HOCM using CE MRI, and correlate the findings to
procedural and infarct-related parameters and early clinical
outcome.
METHODS
Patients. The study protocol was approved by the Com-
mittee on Research Involving Human Subjects and the
Medical Ethics Committee of the VU University Medical
Center Amsterdam. All patients with HOCM who were
scheduled for PTSMA were eligible for MRI. The indica-
tion for PTSMA was based on a significant LVOT gradient
as documented by echocardiography and New York Heart
Association (NYHA) functional class II to IV despite
medical treatment. Exclusion criteria were any absolute or
relative contraindication to MRI (e.g., pacemaker, claustro-
phobia), atrial fibrillation, or failure to give informed con-
sent. Twenty-eight patients were initially enrolled. Four
patients were excluded from the final analysis: three required
pacemaker-implantation during or after PTSMA, and one
declined to return for the follow-up examination. The
baseline characteristics of the remaining 24 patients are
listed in Table 1.
Echocardiography. Baseline echocardiographic measure-
ments of IVS and posterior wall thickness, left ventricular
(LV) end-diastolic, and left atrial end-systolic dimensions
are listed in Table 1. The LVOT pressure gradient was
documented by Doppler echocardiography at baseline and
one month after PTSMA. A pressure gradient50 mm Hg
at rest was considered to be significant. Three patients had
a resting gradient 50 mm Hg, and provocation was
applied both at baseline and follow-up using dobutamine
echocardiography and the Valsalva maneuver in two and
one patients, respectively. An increase of the pressure
gradient during provocation to50 mm Hg was considered
significant.
PTSMA procedure. All patients underwent PTSMA in
one of two major referral centers in the Netherlands
(Thoraxcenter Erasmus Medical Center, Rotterdam, 16
patients; St. Antonius Hospital, Nieuwegein, 8 patients).
Using a standard Judkins technique, an A6F pacemaker
lead was placed in the right ventricle, an A6F pigtail
catheter was positioned into the LV, and an A7F Judkins
guiding catheter in the ascending aorta. The LVOT pres-
sure gradient was continuously monitored throughout the
whole procedure. After initial angiography for localizing the
origin of the septal perforating arteries, a 1.5-2.5  10-mm
balloon catheter was introduced over a 0.014-inch guidewire
into the target perforator artery and inflated. Contrast
(Levovist, Schering AG, Berlin, Germany) was then in-
jected through the balloon catheter shaft during simulta-
neous registration of transthoracic two-dimensional echo-
cardiography to determine the part of the myocardium
supplied by the targeted septal artery. If no leakage of
contrast occurred into the LV cavity, ethanol was slowly
(1 ml/min) injected up to a maximum of 5 ml. Five minutes
after ethanol injection, the balloon was deflated and coro-
nary arteriography repeated. A successful procedure was
Abbreviations and Acronyms
CE  contrast-enhanced
CK  creatine phosphokinase
HOCM  hypertrophic obstructive cardiomyopathy
IVS  interventricular septum
LV  left ventricle/ventricular
LVOT  left ventricular outflow tract
MRI  magnetic resonance imaging
NYHA  New York Heart Association
PTSMA  percutaneous transluminal septal myocardial
ablation
Table 1. Patient Characteristics
Characteristics Patients (n  24)
Age (yrs) 52  15
Men/women 11/13
NYHA functional class 2.9  0.4
II/III/IV 3/20/1
Symptoms
Dyspnea 22
Angina 9
Syncope 6
Family history
HCM/sudden death 14/7
Medication
Beta-blockers 16
Calcium-antagonists 12
Diuretics 2
Echocardiographic parameters at baseline
LVOT gradient, mm Hg 87  22
IVS thickness, cm 2.1  0.4
Posterior wall thickness, cm 1.3  0.2
LVEDD, cm 4.5  0.5
LAESD, cm 4.9  0.4
Values expressed as mean  SD.
HCM hypertrophic cardiomyopathy; IVS interventricular septum; LV left
ventricular; LAESD  left atrial end-systolic diameter; LVEDD  left ventricular
end-diastolic diameter; LVOT  left ventricular outflow tract; NYHA  New York
Heart Association.
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defined as the reduction in LVOT pressure gradient of
50% of baseline. If the results were not satisfactory, the
whole procedure, including echocardiography-contrast in-
jection, was repeated in another septal branch.
The total volume of ethanol injected into perforating
arteries of the left anterior descending coronary artery
during the procedure was documented. Plasma creatine
phosphokinase (CK) and CK-MB fraction levels were
determined before and every 6 h after the procedure during
a 24-h period.
MRI. Magnetic resonance imaging was performed 11 
11 days before and 32 9 days after PTSMA on a 1.5 Tesla
clinical scanner (Sonata, Siemens, Erlangen, Germany),
using a four-element phased-array body radiofrequency
receiver coil. All images were acquired with electrocardio-
gram gating and during repeated breath-holds of 10 to 15 s,
depending on heart rate. After localizing scouts, cine images
were acquired using a segmented steady-state-free preces-
sion sequence in three long-axis views (two-, three-, and
four-chamber view) and in multiple short-axis views every
10 mm, covering the whole LV from base to apex. Scan
parameters were: temporal resolution 34 ms, TR 3.0 ms,
TE 1.5 ms, typical voxel size 1.4  1.8  5 mm3.
Contrast-enhanced images were acquired 15 to 20 min after
intravenous administration of 0.2 mmol/kg gadolinium-
DTPA in the same views used in cine MRI, using a
two-dimensional segmented inversion-recovery prepared
gradient-echocardiography sequence (TE 4.4 ms, TR
9.8 ms, inversion time 250 to 300 ms, typical voxel size
1.3  1.6  5 mm3) (19,20). Contrast-enhanced images
were acquired in all patients at follow-up MRI. As small
patchy areas of hyperenhancement were noted in the IVS
outside the infarcted region, CE imaging was added to the
baseline protocol in patients 11 to 24.
Data analysis. Contrast-enhanced images, cine images,
and catheterization data were analyzed separately, and all
observers were blinded to the results of the other
investigations.
ANALYSIS OF CE IMAGES. Contrast-to-noise ratio of the
hyperenhanced area versus a remote nonenhanced myocar-
dial area was measured on the short-axis slice demonstrating
the largest area of hyperenhancement. Contrast-to-noise
ratio was calculated using regions of interest and defined as:
(SIhyperenhanced  SIremote)/noise, where SI is signal inten-
sity, and noise is expressed as the SI SD in a background
region of interest. Myocardial infarction size after PTSMA
was measured by manual tracing of the hyperenhanced
areas. The hyperenhanced area was defined as the area
within the septal myocardium with pixel SI values4 SD of
remote, nonenhanced myocardium. Central dark zones
within the area of hyperenhancement were included.
ANALYSIS OF CINE IMAGES. Left ventricular parameters,
including end-diastolic volume, end-systolic volume, ejec-
tion fraction, total and septal myocardial mass, and maxi-
mum end-diastolic IVS thickness at the infarct site and
posterior wall thickness were quantified using the MASS
software package (MEDIS, Leiden, the Netherlands). En-
docardial and epicardial borders were outlined manually in
end-diastolic and end-systolic frames of all short-axis slices.
Papillary muscles were included in the assessment of
LV mass. The IVS was defined as the myocardium between
the anterior and posterior junctions of the right ventricle to
the LV.
ANALYSIS OF CORONARY ARTERIOGRAMS. All coronary ar-
teriograms were analyzed and scored in consensus by two
experienced interventional cardiologists (J.M.t.B., J.V.),
who were blinded to the magnetic resonance results. The
number of septal perforating arteries, the target artery, and
the ablation site within the target artery were registered.
Statistical analysis. Results are expressed as mean  SD.
Paired t tests were used to evaluate the changes of LV mass
and volumes after PTSMA. Linear regression analysis was
used to analyze the relationship between myocardial infarc-
tion size (outcome variable) and cardiac enzymes, the
volume of ethanol administered during the ablation proce-
dure, total LV and septal mass reduction, and LVOT
gradient reduction. The analyses were adjusted for age, and
the results are presented as age-adjusted standardized re-
gression coefficients (), which can be interpreted as partial
correlation coefficients. The Mann-Whitney U test was
used to evaluate the correlation between different infarction
locations and myocardial infarction size, the volume of
ethanol administered, and LVOT gradient reduction.
All statistical analyses were performed with SPSS
(version 11.0), and significance was set at a p value 0.05.
RESULTS
Mean volume of ethanol injected was 3.3  1.7 ml, and
mean peak CK and CK-MB release was 1,592  775 U/l
and 198  84 U/l, respectively. One month after PTSMA,
mean LVOT pressure gradient decreased from 87 22 mm
Hg to 23  29 mm Hg (p  0.01), and mean NYHA class
improved significantly from 2.9  0.3 to 1.7  0.6 (p 
0.01). During the follow-up period, none of the patients
experienced syncope, and there were no documented ven-
tricular arrhythmias.
CE MRI at baseline. In 14 patients, CE imaging was
performed before PTSMA. In 10 patients, small patchy
areas of hyperenhanced myocardium were observed in the
IVS, located centrally in the ventricular wall and predomi-
nantly at the junctions of the right and LV free walls. The
number of focal areas of hyperenhancement per patient
was 4  1.5, representing an average mass of 0.5  0.4 g
per area. The contrast-to-noise ratio of these areas was
7  4. Figure 1A shows an example of focal contrast-
enhancement in a patient before PTSMA.
CE MRI after PTSMA—infarct size. At follow-up, a
clearly demarcated area of hyperenhancement was visualized
in the basal part of the IVS in all patients. No patient had
evidence of infarction-related hyperenhancement outside
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the target area. The contrast-to-noise ratio of hyperen-
hanced areas was 26  7. Mean myocardial infarction size
was 20  9 g (range, 5 to 41 g), involving 10  5% of the
post-ablation total LV mass and 31  16% of the septal
myocardial mass. Figures 1B and 2 show examples of
ethanol-induced infarctions.
Figure 1. Contrast-enhanced short-axis images before (A) and after percutaneous transluminal septal myocardial ablation (PTSMA) (B) in a patient with
hypertrophic obstructive cardiomyopathy. Before PTSMA, a slightly enhanced myocardial region is apparent in the anterobasal wall of the interventricular
septum. After PTSMA, the ethanol-induced infarction can be seen as a clearly demarcated area of hyperenhancement.
Figure 2. Contrast-enhanced images 20 min after intravascular administration of gadolinium-DTPA in two patients with hypertrophic obstructive cardiomy-
opathy one month after percutaneous transluminal septal myocardial ablation. (A, B) Three-chamber view and short-axis view in a patient with transmural septal
infarction. (C, D) Comparable views in a patient with myocardial infarction located exclusively on the right ventricular side of the interventricular septum.
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Changes in LV mass and volumes. End-diastolic IVS
thickness measured at the site of infarction decreased from
2.1  0.4 cm at baseline to 1.6  0.5 cm at follow-up (p 
0.01). Total LV myocardial mass decreased significantly
from 219  64 g at baseline to 205  64 g after PTSMA
(p  0.001). Septal myocardial mass decreased from 76 
25 g pre-PTSMA to 68  22 g post-PTSMA (p  0.01).
The reduction in total LV mass was larger than that in
septal mass only (p  0.01). The reduction in remote
myocardial mass (i.e., excluding the septal mass) was statis-
tically significant (p  0.01). At follow-up, LV end-
diastolic volumes were unchanged (153  41 ml vs. 154 
38 ml). A significant increase of LV end-systolic volumes
was observed (47  14 ml vs. 53  17 ml; p  0.03), with
a concurrent decrease in LV ejection fraction (69  5% vs.
67  5%; p  0.01). Changes of LV parameters are
summarized in Table 2.
Correlation between infarct size and other parameters.
Linear regression analysis showed significant associations
between myocardial infarction size and both peak CK and
CK-MB after PTSMA. The age-adjusted standardized
regression coefficients () were 0.53 (p  0.01) and 0.67
(p  0.01), respectively (Fig. 3). Myocardial infarction size
also correlated with the volume of ethanol administered
( 0.47, p 0.02; Fig. 4), total and septal mass reduction
(  0.50, p  0.02;   0.73, p  0.01, respectively), and
the reduction in the LVOT pressure gradient measured by
Doppler echocardiography (  0.63, p  0.01; Fig. 3).
CE MRI after PTSMA—infarct location. The area of
hyperenhancement was located exclusively on the right
ventricular side of the IVS in seven patients, exclusively on
the LV side of the IVS in two patients, and extended
transmurally throughout the IVS in 15 patients. Examples
of a patient with transmural extent and a patient with
exclusively right-sided location of septal infarction are
shown in Figure 2. In the seven patients with exclusively
right-sided hyperenhancement infarct size, septal mass re-
duction and reduction in LVOT gradient were smaller
(10  4 g vs. 23  8 g; 2.5  1.3 g vs. 9.4  4.0; and
30  28 mm Hg vs. 78  22 mm Hg; all p  0.01). The
volume of ethanol infused during the ablation procedure
tended to be lower (2.6  1.2 ml vs. 3.6  1.8 ml, p 
0.19). In these patients, mean NYHA functional class
improved from 3.1  0.4 to 2.3  0.5 and, in the
transmurally infarcted patients, from 2.8 0.4 to 1.4 0.5.
The two patients without symptomatic improvement had a
right-sided location of the septal infarction without reduc-
Table 2. Cine MRI and Clinical Parameters Before and
1 Month After PTSMA
Baseline Follow-Up p Value
Cine MRI parameters (cm)
IVS thickness at infarct site (cm) 2.1  0.4 1.6  0.5 p  0.01
LV PW thickness (cm) 0.8  0.2 0.8  0.1 NS
End-diastolic volume (ml) 153  41 154  38 NS
End-systolic volume (ml) 47  14 53  17 p  0.03
LV ejection fraction (%) 69  5 67  5 p  0.01
Total LV mass (g) 219  64 205  64 p  0.01
Septal mass (g) 76  25 68  22 p  0.01
Clinical parameters
NYHA functional class 2.9  0.4 1.7  0.6 p  0.01
LVOT gradient, mm Hg 87  22 23  29 p  0.01
Values expressed as mean  SD.
IVS  interventricular septum; LV  left ventricular; LVOT  left ventricular
outflow tract; MRI  magnetic resonance imaging; NS  statistically not significant;
NYHANew York Heart Association; PTSMA percutaneous transluminal septal
myocardial ablation; PW  posterior wall.
Figure 3. Correlation of myocardial infarction size and peak creatine
phosphokinase (CK)-MB, reduction in septal mass, and the reduction in
the left ventricular outflow tract (LVOT) pressure gradient after percuta-
neous transluminal septal myocardial ablation. The age-adjusted standard-
ized regression coefficient () and the significance (p value) are given.
SEE  standard error of the estimate.
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tion in the LVOT gradient. The infarction size of these two
patients was 7.3 g and 10.2 g, respectively.
Correlation between infarct location and coronary abla-
tion site. The average number of septal perforating arteries
per patient was 3.6  0.8 (range, 2 to 6). The target artery
was the first, second, and third perforator in 13, 11, and 2
patients, respectively. In two patients, ethanol infusion was
repeated after 20 min in a second artery, because of insufficient
gradient reduction after the first ethanol infusion.
In the 15 patients with transmural infarction and the two
patients with left-sided infarction of the IVS, PTSMA was
performed proximal to the first bifurcation of the target
artery. In the seven patients with exclusively right-sided
hyperenhancement of the IVS, PTSMA was performed
distal to the first bifurcation of the target artery in four and
more distal than usual in a target artery without side
branches in one.
DISCUSSION
Our findings demonstrate that CE MRI allows the detailed
evaluation of the PTSMA-induced myocardial infarction in
symptomatic patients with HOCM. The quantified infarc-
tion size was significantly correlated to cardiac enzyme
release, volume of ethanol administered, total LV and septal
mass reduction, and LVOT pressure gradient reduction.
Also, patients with an exclusively right-sided location of the
infarction within the IVS had significantly smaller infarc-
tion size and less gradient reduction.
Mechanism of hyperenhancement. After coronary artery
occlusion, the extracellular contrast agent gadolinium-
DTPA accumulates in infarcted regions of the myocardium
that are necrotic and irreversibly damaged (21). In (sub)-
acute infarction, this is the result of altered wash-in and
wash-out characteristics and an increased volume of distri-
bution caused by myocyte membrane disrupture (20,22).
The mechanism of contrast agent accumulation in
PTSMA-induced infarctions may be similar, due to the
direct toxic, osmotic, and thrombotic effects of ethanol
spreading throughout the myocardial tissue (23). Because
our data were acquired one month after PTSMA, at a time
when the infarcted myocardium is likely to have entered the
chronic phase, other mechanisms like passive diffusion of
the contrast agent within enlarged interstitial compartments
of the collagen matrix in fibrous scar may have played a role
(21). This mechanism may also explain the presence of
patchy focal areas of hyperenhancement that we found in
the majority of patients that underwent CE MRI before
PTSMA. Choudhury et al. (24) recently reported the
presence of multiple foci of patchy hyperenhancement in the
majority of a group of asymptomatic patients with HCM.
They found that these areas were predominantly located in
the middle third of the ventricular wall, at the junction of
the septum and right ventricular free wall, which is similar
to our findings. The clinical significance of these areas is
unknown, but they may act as a substrate for the develop-
ment of ventricular arrhythmias (25).
Size and location of myocardial infarction. The range of
myocardial infarction size was large (5 to 41 g). Factors that
may influence infarction size include differences in septal
coronary anatomy, position of the inflated balloon within
the target artery during ethanol infusion, and volume of
ethanol administered.
In seven patients, infarction was located exclusively on the
right ventricular side of the septum. These patients had
smaller infarction size and less reduction in LVOT gradient,
and two patients reported no symptomatic improvement. In
contrast with patients with transmural or exclusively left-
sided septal infarction, balloon position during ethanol
infusion was frequently distal to a bifurcation. Currently
available autopsy data of septal coronary anatomy do not
provide a conclusive explanation for the differences in
location of the ablation injury (26). Our findings suggest
that an exclusively right-sided septal infarction may be
related to the ablation site.
Effect of PTSMA on LV mass and volumes. Previous
echocardiographic studies have demonstrated a significant
reduction in LV mass one year after PTSMA. This was not
only due to thinning of septal myocardium, but also to a
decrease of wall thickness throughout the LV circumference
(27,28). The accuracy and reproducibility of MRI enabled
us to detect small changes in LV and septal mass as early as
one month after PTSMA (29). In our study, the reduction
in total LV mass significantly exceeded the reduction in
septal mass, and the reduction in remote myocardial mass
proved statistically significant. This may be explained by the
reduction in LVOT obstruction that may have caused early
regression of (secondary) LV hypertrophy by decreasing LV
pressure and wall stress. An alternative explanation could be
that ethanol infusion induced infarcts in other parts of the
LV wall, by distributing through the capillary network.
However, we found no evidence of induced myocardial
infarction outside the target area, despite the very sensitive
nature of CE MRI to visualize discrete microinjury (30).
The septal infarction caused wall thinning and loss
of regional wall thickening, which led to a small, but
Figure 4. Correlation of the volume of ethanol (ml) injected and myocar-
dial infarction size (g) after percutaneous transluminal septal myocardial
ablation. The age-adjusted standardized regression coefficient () and the
significance (p value) are given.
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significant, increase in LV end-systolic volume. Left ven-
tricular end-diastolic volume was unchanged, and, as a
result, ejection fraction slightly decreased. Although the
changes were only small, they illustrate again the effects of
ethanol-induced infarction. Further study is necessary to
evaluate the long-term effects of PTSMA on LV mass and
volumes.
Study limitations. The total number of patients in our
study group was limited. Three patients (11% of the initial
study group) could not undergo follow-up MRI because a
procedure-related atrioventricular block necessitated
pacemaker-implantation. Infarct size according to peak
CK-MB in these three patients was similar to the study
group (148 29 vs. 198 84 U/l, pNS), suggesting that
infarct location may be an important factor for the devel-
opment of conduction abnormalities.
The foci of patchy hyperenhancement that were demon-
strated in patients with HOCM may have interfered with
determination of the infarction size. Generally, they would
have caused an overestimation of the infarction size, by
overlap of pre-existing foci and ethanol-induced infarction.
However, it is unlikely that these areas have significantly
influenced our results, because the size was small relative to
the procedure-related infarction size.
Clinical implications. At present, the optimal size and
location of the myocardial infarction with respect to clinical
outcome is not known. Theoretically, the objective is to
abolish the LVOT gradient by inducing an infarction in the
basal septum with the smallest possible amount of myocar-
dial damage, located at the site of maximal mitral-septal
contact. A catheter position proximal in the target septal
perforator artery may increase the success rate of PTSMA,
but should be weighted against the possible risks of proxi-
mal balloon inflation, such as injury inflicted on the left
anterior descending artery or the potential of slippage of the
inflated balloon with retrograde ethanol leakage.
During PTSMA, temporary balloon inflation and selec-
tive coronary myocardial contrast echocardiography are used
to probe the risk area (14,23). Although contrast echocar-
diography is helpful in selecting the target location of
ablation and septal branch, it does not allow transmural
evaluation of the myocardium and may, therefore, not be
able to reliably predict the adverse occurrence of right-sided
septal infarction. Additional studies are needed to explore
the relation between the area at risk as estimated by contrast
echocardiography and the ultimate size and location of the
inflicted septal infarction.
In conclusion, we found that CE MRI was an excellent
technique for the quantitative evaluation of septal myo-
cardial infarction induced by PTSMA. The correlation
between size and location of the infarction and early
outcome provides important feedback and may help to
optimize this promising therapeutic option in patients with
HOCM.
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